Moderna initiates phase III study of RSV vaccine

The US-based biotech company now enters the last phase with its vaccine candidate against RSV.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
by VICTOR EMIL KRISTENSEN, translated by daniel pedersen

US-based Moderna is entering the final sprint in the race to have the first vaccine against respiratory syncytial virus (RSV), as reported by Danish business daily Børsen in connection with a company press release, which declared that two successful phase II trials have opened the pathway to a phase III study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading